Absence of the inflammasome adaptor ASC reduces hypoxia-induced pulmonary hypertension in mice

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 309, Issue 4, 2015, Pages L378-L387

  Cero, Fadila Telarevic ^a   Hillestad, Vigdis ^a   Sjaastad, Ivar ^a,b   Yndestad, Arne ^a,b   Aukrust, Pål ^b,c   Ranheim, Trine ^a,b   Lunde, Ida Gjervold ^a,d   Olsen, Maria Belland ^a,b   Lien, Egil ^e,f   Zhang, Lili ^a   Haugstad, Solveig Bjærum ^a   Løberg, Else Marit ^a   Christensen, Geir ^a   Larsen, Karl Otto ^a   Skjønsberg, Ole Henning ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Inflammation; Innate immunity; Pulmonary vasculature

Indexed keywords

ADAPTOR PROTEIN; ADAPTOR PROTEIN APOPTOSIS ASSOCIATED SPECK LIKE PROTEIN CONTAINING A CASPASE RECRUITMENT DOMAIN; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; APOPTOSIS REGULATORY PROTEIN; COLLAGEN; PYCARD PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; HYPOXIA-INDUCED PULMONARY HYPERTENSION; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; LUNG HOMOGENATE; LUNG PARENCHYMA; MACROPHAGE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; ANIMAL; ARTERY; BLOOD; C57BL MOUSE; CELL HYPOXIA; GENETICS; HEART RIGHT VENTRICLE HYPERTROPHY; IMMUNOLOGY; KNOCKOUT MOUSE; LEUKOCYTE; LUNG; METABOLISM; PATHOLOGY; PULMONARY HYPERTENSION; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; ARTERIES; CELL HYPOXIA; COLLAGEN; GENE EXPRESSION; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INFLAMMASOMES; INTERLEUKIN-18; LEUKOCYTES; LUNG; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; VENTRICULAR REMODELING;

EID: 84939446887     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00342.2014     Document Type: Article

References (56)

1. Andersen CU, Mellemkjær S, Nielsen-Kudsk JE, Bendstrup E, Hilberg O, Simonsen U. Pulmonary hypertension in chronic obstructive and interstitial lung diseases. Int J Cardiol 168: 1795-1804, 2013.
2. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 121: 2045-2066, 2010.
3. Ball MK, Waypa GB, Mungai PT, Nielsen JM, Czech L, Dudley VJ, Beussink L, Dettman RW, Berkelhamer SK, Steinhorn RH, Shah SJ, Schumacker PT. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1. Am J Respir Crit Care Med 189: 314-324, 2014.
4. Bauer EM, Shapiro R, Zheng H, Ahmad F, Ishizawar D, Comhair SA, Erzurum SC, Billiar TR, Bauer PM. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med 18: 1509-1518, 2012.
5. Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N, Weiser-Evans MC, Harral J, Irwin DC, Anwar A, Yeager ME, Li M, Watson PA, Nemenoff RA, Buttrick PM, Stenmark KR, McKinsey TA. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res 110: 739-748, 2012.
6. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF- B- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 281: 15099-15109, 2006.
7. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 34: 50s-59s, 2001.
8. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, Walker C, Westwick J, Thomas M. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 184: 1171-1182, 2011.
9. dos Santos G, Kutuzov MA, Ridge KM. The inflammasome in lung diseases. Am J Physiol Lung Cell Mol Physiol 303: L627-L633, 2012.
10. Eltom S, Stevenson CS, Rastrick J, Dale N, Raemdonck K, Wong S, Catley MC, Belvisi MG, Birrell MA. P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PLoS One 6: e24097, 2011.
11. Espe EK, Aronsen JM, Skrbic B, Skulberg VM, Schneider JE, Sejersted OM, Zhang L, Sjaastad I. Improved MR phase-contrast velocimetry using a novel nine-point balanced motion-encoding scheme with increased robustness to eddy current effects. Magn Reson Med 69: 48-61, 2013.
12. Fix C, Bingham K, Carver W. Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine 53: 19-28, 2011.
13. Fujita M, Ye Q, Ouchi H, Nakashima N, Hamada N, Hagimoto N, Kuwano K, Mason RJ, Nakanishi Y. Retinoic acid fails to reverse emphysema in adult mouse models. Thorax 59: 224-230, 2004.
14. George J, D’Armiento J. Transgenic expression of human matrix metalloproteinase-9 augments monocrotaline-induced pulmonary arterial hypertension in mice. J Hypertens 29: 299-308, 2011.
15. Groth A, Vrugt B, Brock M, Speich R, Ulrich S, Huber LC. Inflammatory cytokines in pulmonary hypertension. Respir Res 15: 47, 2014.
16. Hagood JS, Mangalwadi A, Guo B, MacEwen MW, Salazar L, Fuller GM. Concordant and discordant interleukin-1-mediated signaling in lung fibroblast thy-1 subpopulations. Am J Respir Cell Mol Biol 26: 702-708, 2002.
17. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S, Kitasato Y, Kawayama T, Imaizumi T, Yamada K, Young HA, Aizawa H. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med 176: 49-62, 2007.
18. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151: 1628-1631, 1995.
19. Imaoka H, Hoshino T, Takei S, Kinoshita T, Okamoto M, Kawayama T, Kato S, Iwasaki H, Watanabe K, Aizawa H. Interleukin-18 production and pulmonary function in COPD. Eur Respir J 31: 287-297, 2008.
20. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 45: 173-202, 2002.
21. Kanneganti TD, Özören N, Body-Malapel M, Amer A, Park JH, Franchi L, Whitfield J, Barchet W, Colonna M, Vandenabeele P, Bertin J, Coyle A, Grant EP, Akira S, Núñez G. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440: 233-236, 2006.
22. Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity 36: 464-476, 2012.
23. Kim HJ, Kim MY, Hwang JS, Kim HJ, Lee JH, Chang KC, Kim JH, Han CW, Kim JH, Seo HG. PPAR inhibits IL-1-stimulated proliferation and migration of vascular smooth muscle cells via up-regulation of IL-1Ra. Cell Mol Life Sci 67: 2119-2130, 2010.
24. Larsen KO, Lygren B, Sjaastad I, Krobert KA, Arnkværn K, Florholmen G, Larsen AK, Levy FO, Taskén K, Skjønsberg OH, Christensen G. Diastolic dysfunction in alveolar hypoxia: a role for interleukin-18-mediated increase in protein phosphatase 2A. Cardiovasc Res 80: 47-54, 2008.
25. Larsen KO, Yndestad A, Sjaastad I, Løberg EM, Goverud IL, Halvorsen B, Jia J, Andreassen AK, Husberg C, Jonasson S, Lipp M, Christensen G, Aukrust P, Skjønsberg OH. Lack of CCR7 induces pulmonary hypertension involving perivascular leukocyte infiltration and inflammation. Am J Physiol Lung Cell Mol Physiol 301: L50-L59, 2011.
26. Lee FY, Lu HI, Zhen YY, Leu S, Chen YL, Tsai TH, Chung SY, Chua S, Sheu JJ, Hsu SY, Chang HW, Sun CK, Yip HK. Benefit of combined therapy with nicorandil and colchicine in preventing monocrotaline-induced rat pulmonary arterial hypertension. Eur J Pharm Sci 50: 372-384, 2013.
27. Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3 inflammasome. Immunol Rev 243: 152-162, 2011.
28. Li G, Xu YL, Ling F, Liu AJ, Wang D, Wang Q, Liu YL. Angiotensinconverting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels. Chin Med J 125: 1381-1388, 2012.
29. Maron BA, Oldham WM, Chan SY, Vargas SO, Arons E, Zhang YY, Loscalzo J, Leopold JA. Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation 130: 168-179, 2014.
30. Merklinger SL, Wagner RA, Spiekerkoetter E, Hinek A, Knutsen RH, Kabir MG, Desai K, Hacker S, Wang L, Cann GM, Ambartsumian NS, Lukanidin E, Bernstein D, Husain M, Mecham RP, Starcher B, Yanagisawa H, Rabinovitch M. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circ Res 97: 596-604, 2005.
31. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 20-22, 2005.
32. Pisarcik S, Maylor J, Lu W, Yun X, Undem C, Sylvester JT, Semenza GL, Shimoda LA. Activation of hypoxia-inducible factor-1 in pulmonary arterial smooth muscle cells by endothelin-1. Am J Physiol Lung Cell Mol Physiol 304: L549-L561, 2013.
33. Postlethwaite AE, Raghow R, Stricklin GP, Poppleton H, Seyer JM, Kang AH. Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 and . J Cell Biol 106: 311-318, 1988.
34. Pugliese SC, Poth JM, Fini MA, Olschewski A, El Kasmi KC, Stenmark KR. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am J Physiol Lung Cell Mol Physiol 308: L229-L252, 2015.
35. Pullamsetti SS, Savai R, Janssen W, Dahal BK, Seeger W, Grimminger F, Ghofrani HA, Weissmann N, Schermuly RT. Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clin Microbiol Infect 17: 7-14, 2011.
36. Rabinovitch M, Gamble W, Nadas AS, Miettinen OS, Reid L. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol Heart Circ Physiol 236: H818-H827, 1979.
37. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75: 346-359, 2008.
38. Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol 13: 333-342, 2012.
39. Reynolds PR, Mucenski ML, Le Cras TD, Nichols WC, Whitsett JA. Midkine is regulated by hypoxia and causes pulmonary vascular remodeling. J Biol Chem 279: 37124-37132, 2004.
40. Rich S. Right ventricular adaptation and maladaptation in chronic pulmonary arterial hypertension. Cardiol Clin 30: 257-269, 2012.
41. Ross DJ, Strieter RM, Fishbein MC, Ardehali A, Belperio JA. Type I immune response cytokine-chemokine cascade is associated with pulmonary arterial hypertension. J Heart Lung Transplant 31: 865-873, 2012.
42. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 10: 6, 2009.
43. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 94: 1101-1108, 2004.
44. Schreier D, Hacker T, Song G, Chesler N. The role of collagen synthesis in ventricular and vascular adaptation to hypoxic pulmonary hypertension. J Biomech Eng 135: 021018, 2013.
45. Schroder K, Tschopp J. The inflammasomes. Cell 140: 821-832, 2010.
46. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104: 236-244; 228p following 244, 2009.
47. Tabel GM, Whittaker P, Vlachonassios K, Sonawala M, Chandraratna PA. Collagen fiber morphology determines echogenicity of myocardial scar: implications for image interpretation. Echocardiography 23: 103-107, 2006.
48. Tran HB, Lewis MD, Tan LW, Lester SE, Baker LM, Ng J, Hamilton-Bruce MA, Hill CL, Koblar SA, Rischmueller M, Ruffin RE, Wormald PJ, Zalewski PD, Lang CJ. Immunolocalization of NLRP3 inflammasome in normal murine airway epithelium and changes following induction of ovalbumin-induced airway inflammation. J Allergy 2012: 819176, 2012.
49. Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10: 210-215, 2010.
50. Vermeersch P, Buys E, Pokreisz P, Marsboom G, Ichinose F, Sips P, Pellens M, Gillijns H, Swinnen M, Graveline A, Collen D, Dewerchin M, Brouckaert P, Bloch KD, Janssens S. Soluble guanylate cyclasealpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia. Circulation 116: 936-943, 2007.
51. Villegas LR, Kluck D, Field C, Oberley-Deegan RE, Woods C, Yeager ME, El Kasmi KC, Savani RC, Bowler RP, Nozik-Grayck E. Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome. Antioxid Redox Signal 18: 1753-1764, 2013.
52. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB; National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114: 1883-1891, 2006.
53. Voelkel NF, Tuder R. Interleukin-1 receptor antagonist inhibits pulmonary hypertension induced by inflammation. Ann NY Acad Sci 725: 104-109, 1994.
54. Wang Z, Kong L, Kang J, Vaughn DM, Bush GD, Walding AL, Grigorian AA, Robinson JS Jr, Nakayama DK. Interleukin-1 induces migration of rat arterial smooth muscle cells through a mechanism involving increased matrix metalloproteinase-2 activity. J Surg Res 169: 328-336, 2011.
55. Woldbæk PR, Strømme TA, Sande JB, Christensen G, Tønnessen T, Ilebekk A. Evaluation of a new fiber-optic pressure recording system for cardiovascular measurements in mice. Am J Physiol Heart Circ Physiol 285: H2233-H2239, 2003.
56. Zören N, Masumoto J, Franchi L, Kanneganti TD, Body-Malapel M, Ertürk I, Jagirdar R, Zhu L, Inohara N, Bertin J, Coyle A, Grant EP, Núñez G. Distinct roles of TLR2 and the adaptor ASC in IL-1/IL-18 secretion in response to Listeria monocytogenes. J Immunol 176: 4337-4342, 2006.